A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Launched by JUNO THERAPEUTICS, INC., A BRISTOL-MYERS SQUIBB COMPANY · Jan 17, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on studying the long-term safety of a treatment called lisocabtagene maraleucel (often referred to as liso-cel) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to gather information about how well this treatment works over time and to ensure it remains safe for patients who have previously received it. The trial is currently recruiting participants who have had at least one infusion of liso-cel specifically for their CLL or SLL.

To be eligible for the study, participants must have received the treatment as approved in the United States, and they should not be involved in other investigational studies at the same time. If you decide to participate, you can expect to be monitored for the safety and effectiveness of the treatment over an extended period. This study is important because it helps gather valuable information that can improve future treatments for CLL and SLL patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA
• Exclusion Criteria:
• • Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion
• • Patients treated with non-conforming CAR T-cell product